Comparative Pharmacology
Head-to-head clinical analysis: ELFABRIO versus FABRAZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELFABRIO versus FABRAZYME.
ELFABRIO vs FABRAZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human α-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal α-galactosyl groups, thereby reducing accumulation in tissues.
Fabrazyme (agalsidase beta) is a recombinant human alpha-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal alpha-galactosyl residues, thereby reducing accumulation of these substrates in tissues.
1 mg/kg intravenously over 2 hours every 2 weeks.
1 mg/kg intravenously every 2 weeks infused over 4-6 hours.
None Documented
None Documented
Terminal elimination half-life approximately 0.5–1 hour; short half-life necessitates twice-weekly intravenous dosing.
Terminal elimination half-life ranges from 80 to 120 minutes (1.3-2 hours) in adults, which supports a bi-weekly intravenous dosing regimen.
Primarily eliminated via renal excretion as intact protein; minimal biliary/fecal elimination (<1%).
Primarily eliminated via renal pathways; 55-65% of the administered dose is recovered in urine as unchanged drug, with less than 5% recovered in feces.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy